This trial is testing a new cancer treatment that uses genetically modified T cells to attack prostate cancer cells. The goal is to see if the treatment is safe and works well against the cancer.
2 Primary · 3 Secondary · Reporting Duration: Up to 15 years
50 Total Participants · 1 Treatment Group
Primary Treatment: CART-PSMA-TGFβRDN · No Placebo Group · Phase 1
Age 18+ · Male Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: